NurExone Biologic

NurExone Biologic is developing a revolutionary bio-extracellular vesicle (EV)-based technology drug platform to treat injuries in the central nervous system (CNS). The breakthrough exosome-based technology has demonstrated potential in treating spinal cord injury (SCI) in animal studies. The company has obtained a global exclusive license from the Technion-Israel Institute of Technology, University of Haifa, and Tel Aviv University to develop and commercialize the technology. NurExone Biologic conducted extensive research in collaboration with Professor Shulamit Levenberg's laboratory at the Technion-Israel Institute of Technology and Professor Danny Offen from Tel Aviv University, testing a novel proprietary treatment method using intranasal administration of EVs driven by mesenchymal stem cells loaded with siRNA PTEN, targeting spinal cord lesions in rats with complete SCI. Preclinical results showed effective neuronal growth and significant functional recovery.